Home Discovery of novel obovatol-based phenazine analogs as potential antifungal agents: synthesis and biological evaluation in vitro
Article Publicly Available

Discovery of novel obovatol-based phenazine analogs as potential antifungal agents: synthesis and biological evaluation in vitro

  • Chun Yang EMAIL logo , Lili Song , Zhong Miao , Lingyun Jiang , Ting Li , Xiaoyan Zhi , Xiaojuan Hao and Hui Cao
Published/Copyright: March 1, 2021
Become an author with De Gruyter Brill

Abstract

To explore candidate fungicides from plant secondary metabolites, 16 novel obovatol-type phenazine derivatives were semi-synthesized from obovatol isolated from the leaves of Magnolia obovata Thunb. The antifungal activity of synthesized compounds was investigated in vitro against four phytopathogenic fungi using the spore germination method. The bioassay results showed that eight derivatives (8b, 8g, 8hk, 8i′, and 8k′) exhibited better antifungal activity against Fusarium solani than two positive controls, especially compounds 8b (IC50 = 64.61 μg mL−1) and 8i′ (IC50 = 79.97 μg mL−1) showed pronounced inhibition of spore germination activity against F. solani. They could be used as lead compounds for further structural optimization. Additionally, the preliminary structure-activity relationships (SARs) illustrated that the introduction of a benzene ring monosubstituted with electron-withdrawing groups into the obovatol scaffold could lead to potentially antifungal compounds.

1 Introduction

Plants of the family Magnoliaceae have long been used as the traditional herbs to relieve various ailments because they contain a variety of natural substances with potential biological activity in many oriental countries as, e. g., China, South Korea and Japan [1], [, 2]. Among them, the stem bark, root bark and seeds of Magnolia officinalis Rehder. and Magnolia obovata Thunb. are usually used as important traditional medicines for the treatment of diseases such as headache, stroke, diarrhea, gastrointestinal discomfort, and anxiety [3], [, 4]. Meanwhile, it has been reported that the following bioactive compounds were found in the above two Magnolia species: obovatol (1), honokiol (2), magnolol (3), and 4′-O-methylhonokiol (4) (Figure 1) [5], [6], [7], [8].

Figure 1: Chemical structures of obovatol (1), honokiol (2), magnolol (3), and 4′-O-methylhonokiol (4).
Figure 1:

Chemical structures of obovatol (1), honokiol (2), magnolol (3), and 4′-O-methylhonokiol (4).

Among these compounds, obovatol (1), a naturally occurring lignan bearing a diphenyl ether skeleton, was mainly isolated from the leaves and stem bark of M. obovata Thunb [1], [5], [8]. Recent studies have also shown that there are obovatol trimeric neolignans from the leaves of M. officinalis var. biloba [9]. Compound 1 and its derivatives have received more and more attention due to their excellent biological activities including antifungal [7], [, 10], antitumor [11], anti-inflammatory [12], anxiolytic [13], and neuroprotective activity [14], [, 15], antiplatelet aggregation [16], and the effects in the treatment of Alzheimer’s disease [17]. Moreover, we have prepared a series of obovatol-based Mannich base derivatives in previous research, which also showed excellent and broad-spectrum antifungal activities against phytopathogenic fungi [10]. These results provide a valuable lead compound for further studies to develop botanical antifungal agents. Additionally, the phenazine heterocycle, one of the most important scaffolds in organic chemistry, exists in a variety of compounds which display potential antifungal activity [18], [19], [20]. Several studies have also found that many lead compounds can significantly improve the biological activity after the introduction of phenazine fragment [21], [, 22]. In recent years, the combination of active substructures and natural lead compounds has become an important method for the development of novel green pesticides [23].

Encouraged by the aforementioned interesting results our ongoing efforts focus on the discovery of novel natural product-based pesticides [24], [, 25]. As part of these studies we report here on the synthesis of a series of novel obovatol-based phenazine derivatives and their antifungal activity against four strains of phytopathogenic fungi which was evaluated in vitro. Finally, a preliminary structure-activity relationship (SAR) of the target compounds was also explored.

2 Experimental

2.1 General information

The leaves of M. obovata were collected from Qingdao, Shandong Province, P. R. China and obovatol (1) was isolated from the leaves of M. obovata according to our previously reported procedures [10]. All chemical reagents and solvents were obtained from commercial sources and used without further purification unless otherwise stated in this work. Difenoconazole (>98%) and hymexazole (>99%) were purchased from Aladdin Reagents Co., Ltd. and used as the positive controls. Analytical thin-layer chromatography (TLC) and column chromatography (CC) were performed using silica gel 60 GF254 and silica gel (200–300 mesh) (Qingdao Haiyang Chemical Co., Ltd., Qingdao, China), respectively. Melting points (m.p.) were determined on a SGWX-4B digital melting-point apparatus and are uncorrected (Shanghai INESA Physico optical Instrument Co., Ltd.). 1H NMR (500 MHz) and 13C NMR (125 MHz) were recorded on a Bruker Avance Ⅲ 500 magnetic resonance spectrometer (Bruker, Germany) in deuterochloroform (CDCl3) or deuterated dimethyl sulfoxide (DMSO-d6) with tetramethylsilane (TMS) as internal standard. High resolution electrospray ionization mass spectrometry (HR-ESI-MS) was measured on a Waters Xevo G2-XS QToF spectrometer (Waters Technologies, USA).

2.2 General procedure for the synthesis of phenazine derivatives of obovatol (8a–k, 8h′–8k′, and 8l)

To a stirred solution of obovatol (1, 200 mg, 0.71 mmol) in dry dichloromethane (10 mL) in an ice bath, a solution of concentrated nitric acid (1.42 mmol) in dry dichloromethane (5 mL) was added dropwise while the temperature was maintained below 0 °C. After that, the reaction mixture was allowed to warm up to room temperature naturally and the reaction progress was monitored by TLC analysis. When the reaction was complete after 5 h, the mixture was extracted with dichloromethane (3  × 50 mL) and the combined organic phase was dried over anhydrous Na2SO4 and subsequently concentrated in vacuo. The obtained residue was used directly for the next step. A solution of substituted ortho-Phenylenediamine or 2,3-diaminonaphthalene (1.07 mmol) in CHCl3 (10 mL) was added to a solution of the residue from the previous step in CHCl3 (10 mL) at room temperature. The reaction system was stirred overnight and the mixture was concentrated, and purified by silica gel column chromatography to afford compounds 8ak, 8h′8k′, and 8l in 11.1–24.4% yield (two steps from 1 to 8ak, 8h′8k′, and 8l).

2.2.1 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)phenazine (8a)

Yield: 23.4%, light green powder, m.p. 104.3–104.8 °C. – 1H NMR (500 MHz, CDCl3): δ = 8.38 (d, J = 8.0 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H), 7.80–7.87 (m, 2H), 7.76 (s, 1H), 7.26 (s, 1H), 7.24 (s, 1H), 7.17 (s, 1H), 7.15 (s, 1H), 6.88 (d, J = 1.5 Hz, 1H), 5.96–6.06 (m, 2H), 5.10–5.16 (m, 4H), 3.52 (d, J = 6.5 Hz, 2H), 3.43 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, CDCl3): δ = 154.47, 154.21, 144.07, 143.49, 143.38, 142.43, 137.32, 136.41, 136.36, 135.43, 131.03, 130.36, 130.07, 130.03, 129.14, 121.32, 120.67, 117.45, 116.00, 115.17, 40.64, 39.57. – HRMS ((+)-ESI): m/z = 353.1653 (calcd. 353.1654 for C24H21N2O, [M+H]+).

2.2.2 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-7,8-difluorophenazine (8b)

Yield: 12.4%, light yellow powder, m.p. 118.2–118.4 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 8.22–8.31 (m, 2H), 7.74 (s, 1H), 7.26 (s, 1H), 7.24 (s, 1H), 7.10 (s, 1H), 7.08 (s, 2H), 5.94–6.06 (m, 2H), 5.05–5.15 (m, 4H), 3.58 (d, J = 6.5 Hz, 2H), 3.38 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.68, 152.47, 143.86, 143.55, 140.96, 140.87, 139.46, 139.37, 137.62, 136.05, 135.58, 135.53, 130.09, 121.46, 119.11, 117.28, 117.25, 115.90, 114.63, 114.49, 113.96, 113.82, 39.58, 38.70. – HRMS ((+)-ESI): m/z = 389.1461 (calcd. 389.1465 for C24H19N2OF2, [M+H]+).

2.2.3 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-7,8-dichlorophenazine (8c)

Yield: 16.2%, light yellow powder, m.p. 122.4–122.7 °C. – 1H NMR (500 MHz, CDCl3): δ = 8.51 (s, 1H), 8.36 (s, 1H), 7.71 (s, 1H), 7.26 (s, 1H), 7.25 (s, 1H), 7.14 (s, 1H), 7.13 (s, 1H), 6.90 (d, J = 1.5 Hz, 1H), 5.95–6.06 (m, 2H), 5.10–5.17 (m, 4H), 3.52 (d, J = 6.5 Hz, 2H), 3.43 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, CDCl3): δ = 154.25, 154.12, 144.61, 144.40, 141.94, 140.74, 137.25, 136.73, 136.63, 136.00, 135.11, 134.99, 130.46, 130.15, 129.36, 121.25, 120.51, 117.73, 116.07, 115.95, 40.67, 39.56. – HRMS ((+)-ESI): m/z = 421.0876 (calcd. 421.0874 for C24H19N2OCl2, [M+H]+).

2.2.4 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-7,8-dibromophenazine (8d)

Yield: 14.5%, light yellow powder, m.p. 125.3–125.6 °C. – 1H NMR (500 MHz, CDCl3): δ = 8.72 (s, 1H), 8.58 (s, 1H), 7.71 (s, 1H), 7.26 (s, 1H), 7.24 (s, 1H), 7.14 (s, 1H), 7.12 (s, 1H), 6.90 (d, J = 1.5 Hz, 1H), 5.94–6.06 (m, 2H), 5.10–5.17 (m, 4H), 3.52 (d, J = 6.5 Hz, 2H), 3.43 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, CDCl3): δ = 154.22, 154.15, 144.82, 144.35, 142.23, 141.15, 137.24, 136.79, 136.64, 135.06, 133.98, 132.81, 130.16, 128.26, 127.07, 121.23, 120.49, 117.76, 116.08, 116.01, 40.69, 39.56. – HRMS ((+)-ESI): m/z = 508.9857 (calcd. 508.9864 for C24H19N2OBr2, [M+H]+).

2.2.5 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-6,9-dibromophenazine (8e)

Yield: 24.4%, light yellow liquid. – 1H NMR (500 MHz, DMSO-d6): δ = 8.21 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.0 Hz, 1H), 7.84 (s, 1H), 7.24 (s, 1H), 7.22 (s, 1H), 7.21 (d, J = 1.5 Hz, 1H), 7.15 (s, 1H), 7.14 (s, 1H), 5.93–6.10 (m, 2H), 5.04–5.19 (m, 4H), 3.61 (d, J = 6.5 Hz, 2H), 3.36 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.92, 152.43, 145.38, 143.97, 140.46, 139.17, 137.67, 136.07, 135.87, 135.46, 134.29, 133.52, 129.98, 123.77, 123.06, 121.56, 119.28, 118.66, 117.50, 115.79, 39.63, 38.68. – HRMS ((+)-ESI): m/z = 508.9863 (calcd. 508.9864 for C24H19N2OBr2, [M+H]+).

2.2.6 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-7,8-dimethylphenazine (8f)

Yield: 12.4%, light yellow powder, m.p. 86.5–87.0 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 7.95 (s, 2H), 7.73 (s, 1H), 7.22 (s, 1H), 7.21 (s, 1H), 7.06 (s, 2H), 7.04 (s, 1H), 5.93–6.07 (m, 2H), 5.04–5.16 (m, 4H), 3.56 (d, J = 6.5 Hz, 2H), 3.35 (d, J = 6.5 Hz, 2H), 2.52 (s, 3H), 2.50 (s, 3H). – 13C NMR (125 MHz, DMSO-d6): δ = 155.23, 152.33, 143.42, 142.69, 142.44, 142.27, 141.91, 141.13, 137.70, 136.32, 135.30, 135.05, 129.98, 127.75, 127.18, 122.06, 118.71, 117.10, 117.02, 115.84, 39.60, 38.71, 20.15, 20.04. – HRMS ((+)-ESI): m/z = 381.1967 (calcd. 381.1967 for C26H25N2O, [M+H]+).

2.2.7 Spectroscopic data for 8-allyl-6-(4-allylphenoxy)-1,2,3,4-tetrafluorophenazine (8g)

Yield: 11.5%, orange powder, m.p. 110.7–110.9 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 7.84 (s, 1H), 7.28 (s, 1H), 7.26 (s, 1H), 7.18 (s, 1H), 7.15 (s, 1H), 7.13 (s, 1H), 5.95–6.08 (m, 2H), 5.06–5.17 (m, 4H), 3.61 (d, J = 6.5 Hz, 2H), 3.39 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.34, 152.59, 145.78, 143.29, 137.56, 135.86, 135.74, 130.13, 121.39, 119.31, 118.21, 117.50, 115.88, 39.57, 38.66. – HRMS ((+)-ESI): m/z = 425.1275 (calcd. 425.1277 for C24H17N2OF4, [M+H]+).

2.2.8 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-7-nitrophenazine (8h)

Yield: 18.5%, orange powder, m.p. 113.4–113.8 °C. – 1H NMR (500 MHz, CDCl3): δ = 9.16 (s, 1H), 8.53 (s, 2H), 7.78 (s, 1H), 7.29 (s, 1H), 7.27 (s, 1H), 7.17 (s, 1H), 7.15 (s, 1H), 6.96 (s, 1H), 5.96–6.06 (m, 2H), 5.10–5.20 (m, 4H), 3.55 (d, J = 5.0 Hz, 2H), 3.44 (d, J = 6.0 Hz, 2H). – HRMS ((+)-ESI): m/z = 398.1502 (calcd. 398.1505 for C24H20N3O3, [M+H]+).

2.2.9 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-8-nitrophenazine (8h′)

Yield: 16.2%, orange powder, m.p. 63.7–64.1 °C. – 1H NMR (500 MHz, CDCl3): δ = 9.35 (s, 1H), 8.57 (d, J = 7.0 Hz, 1H), 8.36 (d, J = 7.5 Hz, 1H), 7.77 (s, 1H), 7.29 (s, 1H), 7.27 (s, 1H), 7.17 (s, 1H), 7.15 (s, 1H), 6.94 (s, 1H), 5.96–6.07 (m, 2H), 5.11–5.20 (m, 4H), 3.56 (s, 2H), 3.45 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, CDCl3): δ = 154.31, 154.07, 147.81, 146.32, 145.68, 145.06, 140.37, 137.81, 137.20, 136.91, 134.85, 131.20, 130.26, 127.27, 123.68, 121.44, 120.56, 117.99, 116.13, 40.80, 39.57. – HRMS ((+)-ESI): m/z = 398.1500 (calcd. 398.1505 for C24H20N3O3, [M+H]+).

2.2.10 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-7-chlorophenazine (8i)

Yield: 12.9%, light yellow powder, m.p. 117.3–117.5 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 8.30 (d, J = 2.0 Hz, 1H), 8.24 (d, J = 9.0 Hz, 1H), 7.90 (dd, J = 9.5, 2.0 Hz, 1H), 7.75 (s, 1H), 7.26 (s, 1H), 7.24 (s, 1H), 7.11 (s, 1H), 7.09 (s, 1H), 7.08 (s, 1H), 5.9–6.07 (m, 2H), 5.05–5.16 (m, 4H), 3.58 (d, J = 6.5 Hz, 2H), 3.38 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.71, 152.70, 144.27, 144.08, 142.98, 140.23, 137.62, 136.00, 135.88, 135.51, 131.59, 131.48, 130.07, 127.36, 121.60, 119.11, 117.31, 117.18, 115.87, 39.62, 38.68. – HRMS ((+)-ESI): m/z = 387.1266 (calcd. 387.1264 for C24H20N2OCl, [M+H]+).

2.2.11 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-8-chlorophenazine (8i′)

Yield: 13.3%, light yellow powder, m.p. 77.4–77.8 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 8.29 (d, J = 2.0 Hz, 1H), 8.21 (d, J = 9.5 Hz, 1H), 7.92 (dd, J = 9.5, 2.0 Hz, 1H), 7.74 (s, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 7.10 (s, 1H), 7.09 (s, 2H), 5.94–6.06 (m, 2H), 5.05–5.16 (m, 4H), 3.57 (d, J = 6.5 Hz, 2H), 3.37 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.73, 152.52, 143.77, 143.75, 141.57, 137.61, 136.14, 136.00, 135.47, 135.19, 132.19, 130.97, 130.05, 127.89, 121.80, 119.08, 117.59, 117.27, 115.86, 39.58, 38.67. – HRMS ((+)-ESI): m/z = 387.1260 (calcd. 387.1264 for C24H20N2OCl, [M+H]+).

2.2.12 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-7-bromophenazine (8j)

Yield: 11.1%, light yellow powder, m.p. 64.7–65.8 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 8.47 (s, 1H), 8.15 (d, J = 9.0 Hz, 1H), 8.00 (d, J = 9.0 Hz, 1H), 7.75 (s, 1H), 7.25 (s, 1H), 7.24 (s, 1H), 7.11 (s, 1H), 7.10 (s, 1H), 7.09 (s, 1H), 5.94–6.06 (m, 2H), 5.05–5.16 (m, 4H), 3.58 (d, J = 6.5 Hz, 2H), 3.38 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.69, 152.70, 144.26, 143.99, 143.27, 140.35, 137.60, 135.99, 135.92, 135.50, 133.83, 131.49, 130.05, 124.95, 121.61, 119.10, 117.30, 117.19, 115.86, 39.61, 38.67. – HRMS ((+)-ESI): m/z = 431.0751 (calcd. 431.0759 for C24H20N2OBr, [M+H]+).

2.2.13 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-8-bromophenazine (8j′)

Yield: 12.5%, light yellow powder, m.p. 102.3–102.7 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 8.46 (s, 1H), 8.13 (d, J = 9.0 Hz, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.74 (s, 1H), 7.25 (s, 1H), 7.23 (s, 1H), 7.10 (s, 1H), 7.09 (s, 2H), 5.94–6.06 (m, 2H), 5.05–5.16 (m, 4H), 3.56 (d, J = 6.5 Hz, 2H), 3.37 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.75, 152.53, 143.82, 141.90, 141.71, 137.61, 136.07, 135.98, 134.54, 131.32, 130.89, 130.04, 124.06, 121.83, 119.06, 117.65, 117.28, 115.85, 39.60, 38.67. – HRMS ((+)-ESI): m/z = 431.0764 (calcd. 431.0759 for C24H20N2OBr, [M+H]+).

2.2.14 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-7-(trifluoromethyl)phenazine (8k)

Yield: 13.0%, light yellow powder, m.p. 55.7–56.3 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 8.63 (s, 1H), 8.44 (d, J = 9.0 Hz, 1H), 8.11 (d, J = 9.0 Hz, 1H), 7.82 (s, 1H), 7.27 (s, 1H), 7.25 (s, 1H), 7.16 (s, 1H), 7.13 (s, 1H), 7.12 (s, 1H), 5.95–6.08 (m, 2H), 5.06–5.18 (m, 4H), 3.61 (d, J = 6.5 Hz, 2H), 3.39 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.64, 152.65, 144.68, 144.53, 142.19, 141.60, 137.61, 137.13, 135.91, 135.62, 131.88, 130.10, 127.53, 125.14, 121.77, 119.14, 118.06, 117.42, 115.88, 39.61, 38.68. – HRMS ((+)-ESI): m/z = 421.1529 (calcd. 421.1528 for C25H20N2OF3, [M+H]+).

2.2.15 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)-8-(trifluoromethyl)phenazine (8k′)

Yield: 12.0%, light yellow powder, m.p. 70.7–71.3 °C. – 1H NMR (500 MHz, DMSO-d6): δ = 8.66 (s, 1H), 8.43 (d, J = 9.5 Hz, 1H), 8.16 (d, J = 8.5 Hz, 1H), 7.83 (s, 1H), 7.27 (s, 1H), 7.26 (s, 1H), 7.15 (s, 1H), 7.14 (s, 1H), 7.12 (s, 1H), 5.95–6.08 (m, 2H), 5.06–5.18 (m, 4H), 3.61 (d, J = 6.5 Hz, 2H), 3.39 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 154.61, 152.73, 145.24, 144.90, 143.59, 140.16, 137.59, 136.79, 135.87, 135.62, 131.26, 130.09, 125.92, 121.72, 119.15, 117.61, 117.41, 115.86, 38.66. – HRMS ((+)-ESI): m/z = 421.1531 (calcd. 421.1528 for C25H20N2OF3, [M+H]+).

2.2.16 Spectroscopic data for 3-allyl-1-(4-allylphenoxy)benzo[b]phenazine (8l)

Yield: 12.6%, dark-red liquid. – 1H NMR (500 MHz, DMSO-d6): δ = 9.00 (s, 1H), 8.97 (s, 1H), 8.23–8.27 (m, 2H), 7.75 (s, 1H), 7.59–7.64 (m, 2H), 7.26 (s, 1H), 7.25 (s, 1H), 7.14 (s, 1H), 7.13 (s, 1H), 7.05 (s, 1H), 5.95–6.09 (m, 2H), 5.06–5.20 (m, 4H), 3.58 (d, J = 6.5 Hz, 2H), 3.38 (d, J = 6.5 Hz, 2H). – 13C NMR (125 MHz, DMSO-d6): δ = 155.45, 152.91, 145.24, 144.10, 140.00, 138.83, 138.17, 138.02, 136.43, 135.84, 134.90, 134.43, 130.54, 128.96, 128.80, 128.43, 127.80, 127.47, 122.42, 119.45, 117.90, 117.59, 116.37, 39.21. – HRMS ((+)-ESI): m/z = 403.1811 (calcd. 403.1810 for C28H23N3O, [M+H]+).

2.3 Crystal structure determination of 8i′

A suitable crystal was selected and examined with a SuperNOVA single-crystal X-ray diffractometer from Agilent Technologies Inc., Santa Clara, CA (USA). Diffraction data were collected at T = 293(2) K using Cu radiation (λ = 1.54184 Å). Using Olex2 [26], the structure was solved with Direct Methods using the program Shelxs [27] and refined with full matrix-least squares minimization using Shelxl [28]. Table 1 summarizes the crystal data and numbers pertinent to data collection and refinement.

Table 1:

The crystallographic data for compound 8i′.

Complex8i′
FormulaC24H19ClN2O
Mr386.86
Cryst. size, mm30.17 × 0.03 × 0.02
Crystal systemOrthorhombic
Space groupPn21a
a, Å19.6165(4)
b, Å4.82370(13)
c, Å21.2345(6)
V, Å32009.30(9)
Z4
Dcalcd, g cm−31.279
μ(Cu), mm−11.8
F(000), e808
hkl range−23 → 20, −5 → 4, −21 → 25
θ range, deg4.2–69.9
Refl. measured9007
Refl. unique2996
Rint0.038
Param. refined/restraints254/6
R(F)/wR(F2)a (I > 2σ(I))0.0448/0.1143
R(F)/wR(F2)a (all refl.)0.0579/0.1274
x (Flack)0.034(17)
GoF (F2)b1.028
Δρfin (max/min), e Å−30.19/−0.18
  1. aR(F) = ||Fo| – |Fc||/Σ|Fo|, wR(F2) = [Σw(Fo2 – Fc2)2w(Fo2)2]1/2, w = [σ2(Fo2) + (0.0650P)2 + 0.1357P]−1, where P = (Max(Fo2, 0) + 2Fc2)/3; bGoF = [Σw(Fo2 – Fc2)2/(nobs – nparam)]1/2.

CCDC 2026867 (8i′) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre viawww.ccdc.cam.ac.uk/data_request/cif.

2.4 Antifungal assay of compounds 8a–k, 8h′–8k′, and 8l

The tested plant pathogenic fungi Alternaria solani, F. solani, Botrytis cinerea, and Colletotrichum orbiculare were provided by the Key Laboratory of Plant Pathology, College of Plant Protection, Shanxi Agricultural University, Taigu, P. R. China. These fungi were grown on potato dextrose agar (PDA) plates at 25 ± 1 °C for 96 h before used for the biological assays and maintained at 4 °C with periodic subculturing. Four tested phytopathogenic fungal strains were cultured at 25 ± 1 °C on potato dextrose agar (PDA) until sporulation. Then, sterile distilled water was poured onto the Petri dishes and the conidia were scraped with a glass rod. The mixture was filtered by quadruple-layer cheesecloth to remove mycelial debris and the spores were obtained and suspended in sterile distilled water. Finally, the spore suspension was diluted to a suitable concentration (30–40 spores per field vision under 100-fold magnification) with sterile water for further testing and an additional 0.5% aqueous glucose solution was added.

All the samples were dissolved in dimethyl sulfoxide (DMSO final concentration ≤ 1%, v/v) and diluted to a series of desired concentrations with aseptic aqueous 0.1% Tween-80 (v/v) solution. Then, the sample solution was further mixed with the prepared spore suspension and 30 μL aliquots of the treated spore suspension were placed on separate glass slides in triplicate. The glass slides containing the spores were incubated in an incubator and kept at a suitable moisture. For different fungal spores, the culture conditions were different. A. solani, F. solani, and C. orbiculare were incubated at 25 ± 1 °C for 3–6 h and B. cinerea was incubated at 20 ± 1 °C for 7 h. The spores were considered to have germinated if the length of the germ tube was at least half the length of the spore. The number and percentage of the germinated spores were calculated in the compound-treated group when the percentage of germinated spores was more than 90% that in the blank control group. 1% aqueous DMSO solution was used as a blank control.

Corrected inhibition rate (in %) of spore germination: (Rc – Rt)/Rc × 100 where Rc is the percentage of germinated spores in the blank control test and Rt represents the percentage of germinated spores in the compound-treated test sample. The experimental data of the antifungal assay were analyzed by Excel 2010 and SPSS 20.0 software for Windows.

3 Results and discussion

Scheme 1: Synthetic route of the preparation of phenazine derivatives of obovatol (8a–k, 8h′–8k′, and 8l).
Scheme 1:

Synthetic route of the preparation of phenazine derivatives of obovatol (8ak, 8h′8k′, and 8l).

3.1 Synthesis and characterization

The isolated obovatol (1) was used as precursor for the further synthetic steps. As depicted in Scheme1, the intermediate 7 was obtained by oxidation of 1 in the presence of concentrated nitric acid. Subsequently, the unpurified 7 was used directly in the next step, and reacted with substituted ortho-Phenylenediamine or 2,3-diaminonaphthalene to produce the target products 8ak, 8h′8k′, and 8l via cyclization reaction. It should be noted that two different products 8hk and 8h′8k′ were obtained after cyclization of each monosubstituted ortho-Phenylenediamine and intermediate 7. Unexpectedly, none of the nitration products 5 and 6 was found when obovatol was treated with concentrated nitric acid. The structures of all the target compounds were characterized by 1H and 13C nuclear magnetic resonance, high-resolution mass spectrometry (HR-MS) and melting points (m.p.). Furthermore, the configuration of compound 8i′ was unambiguously identified by X-ray crystallography which established the crystal and molecular structure (Figure 2, Table 1). This clearly demonstrated that the phenazine heterocycle was introduced into the obovatol skeleton.

Figure 2: The molecular structure of 8i′ in the crystal and atom numbering scheme adopted. Non-H atoms are drawn as ellipsoids at the 50% probability level, hydrogen atoms as spheres with arbitrary radius. Important bond lengths (Å) and angles (°): Cl1–C1 1.732(4), O1–C5 1.368(4), O1–C16 1.406(5), N1–C3 1.347(5), N1–C4 1.343(5), N2–C9 1.338(5), N2–C10 1.341(5); C5–O1–C16 117.9(3), C4–N1–C3 116.2(3), C9–N2–C10 117.5(3), C2–C1–Cl1 120.5(3), C12–C1–Cl1 117.3(3), N1–C3–C2 119.1(3), N1–C3–C10 121.9(4), N1–C4–C5 120.2(3), N1–C4–C9 122.2(3), O1–C5–C4 113.9(3), C6–C5–O1 125.5(3), N2–C9–C4 120.9(3), N2–C9–C8 119.4(3), N2–C10–C3 121.3(4), N2–C10–C11 119.9(3), C17–C16–O1 119.9(4), C21–C16–O1 118.3(4).
Figure 2:

The molecular structure of 8i′ in the crystal and atom numbering scheme adopted. Non-H atoms are drawn as ellipsoids at the 50% probability level, hydrogen atoms as spheres with arbitrary radius. Important bond lengths (Å) and angles (°): Cl1–C1 1.732(4), O1–C5 1.368(4), O1–C16 1.406(5), N1–C3 1.347(5), N1–C4 1.343(5), N2–C9 1.338(5), N2–C10 1.341(5); C5–O1–C16 117.9(3), C4–N1–C3 116.2(3), C9–N2–C10 117.5(3), C2–C1–Cl1 120.5(3), C12–C1–Cl1 117.3(3), N1–C3–C2 119.1(3), N1–C3–C10 121.9(4), N1–C4–C5 120.2(3), N1–C4–C9 122.2(3), O1–C5–C4 113.9(3), C6–C5–O1 125.5(3), N2–C9–C4 120.9(3), N2–C9–C8 119.4(3), N2–C10–C3 121.3(4), N2–C10–C11 119.9(3), C17–C16–O1 119.9(4), C21–C16–O1 118.3(4).

3.2 Antifungal activity

The antifungal activity of derivatives 8ak, 8h′8k′, and 8l against four plant pathogenic fungi in vitro was tested using the spore germination method. As is shown in Table 2, the results revealed that most of compounds lost antifungal activity when compared with the precursor obovatol. Firstly, none of the tested compounds showed antifungal activity against A. solani. On the other hand, we found that eight of the 16 compounds (8b, 8g, 8h–k, 8i′, and 8k′) exhibited better inhibitory activity against F. solani than obovatol and two positive controls (difenoconazole and hymexazole). Specifically, compounds 8b and 8i′ displayed the highest inhibitory activity against F. solani with the IC50 values of 64.61 and 79.97 μg mL−1, respectively, whereas the IC50 values of obovatol was 114.52 μg mL−1 and the positive controls were greater than 500 μg mL−1. These findings may indicate that obovatol phenazine derivatives possess specific inhibitory on F. solani spores. In addition, only compound 8b (IC50 = 223.45 μg mL−1) showed moderate inhibitory effects on B. cinerea spores. Derivatives 8b and 8h exhibited certain antifungal activity against C. orbiculare spores with the IC50 values of 124.75 and 130.19 μg mL−1, respectively. In summary, it can be found that compound 8b showed excellent and broad spectrum antifungal activity, which is worthy of further investigation.

Table 2:

Antifungal activity of target compounds 8ak, 8h′8k′, and 8l against four phytopathogenic fungal spores.

Compd.IC50 ± SDa and 95% CLb in parentheses (values in μg mL−1)
A. solaniF. solaniB. cinereaC. orbiculare
8a>500>500>500>500
8b>50064.61 ± 4.39 (56.56–73.81)223.45 ± 22.27 (183.80–271.65)124.75 ± 5.69 (114.08–136.41)
8c>500>500>500>500
8d>500>500>500>500
8e>500>500>500>500
8f>500>500>500>500
8g>500135.18 ± 8.81 (118.97–153.60)>500>500
8h>500127.12 ± 9.78 (109.32–147.81)>500130.19 ± 8.45 (114.63–147.86)
8h′>500>500>500>500
8i>500168.76 ± 10.67 (149.09–191.03)>500>500
8i′>50079.97 ± 4.38 (71.84–89.02)>500>500
8j>500112.63 ± 9.93 (94.76–133.88)>500>500
8j′>500>500>500>500
8k>500331.01 ± 40.40 (260.58–420.47)>500>500
8k′>500120.17 ± 11.02 (100.39–143.83)>500>500
8l>500>500>500>500
135.97 ± 1.45 (33.24–38.92)114.52 ± 6.04 (99.25–122.21)130.07 ± 9.11 (113.388–149.20)15.73 ± 1.59

12.90–19.19
HYMc127.32 ± 5.73 (116.57–139.07)>50074.33 ± 3.51 (67.75–81.54)260.01 ± 11.57 (238.30–283.70)
DFZc162.22 ± 11.49 (141.19–186.38)>50084.54 ± 3.34 (78.23–91.36)58.71 ± 3.41 (52.39–65.79)
  1. aAll values are presented as means ± SD (n = 3); b95% CL means 95% confidence limit; cHYM and DFZ are hymexazol and difenoconazole, respectively.

The preliminary structure-activity relationship study showed that among the eight compounds with significant inhibitory effect on the spores of F. solani, six compounds (8hk, 8i′, and 8k′) are monosubstituted derivatives, and all of them contain electron-withdrawing groups on the benzene ring (8h: 4-nitrophenyl; 8i/8i′: 3/4-chlorophenyl; 8j: 4-bromophenyl; 8k/8k′: 3/4-trifluoromethylphenyl). This may indicate that the introduction of a monosubstituted electron-withdrawing group containing a benzene ring into obovatol can give rise to further potentially antifungal compounds against F. solani. This finding provides a basis for the further development of effective antifungal agents based on obovatol.

4 Conclusion

In conclusion, sixteen obovatol-based phenazine derivatives were synthesized and their structures were well characterized. The structure of 8i′ was confirmed by single-crystal X-ray diffraction. Their antifungal activities against four phytopathogenic fungal strains were also evaluated in vitro. Among these derivatives, eight compounds (8b, 8g, 8hk, 8i′, and 8k′) exhibited more pronounced antifungal activity against F. solani than two commercial fungicides. Especially compounds 8b and 8i′ showed promising inhibition of spore germination activity against F. solani with the IC50 values of 64.61 and 79.97 μg mL−1, respectively. In addition, compound 8b displayed varying degrees of spore germination inhibition ability against three tested phytopathogenic fungal strains and showed broad-spectrum antifungal effect. The SARs suggested that the introduction of a benzene ring monosubstituted with an electron-withdrawing group into the obovatol could yield to potential antifungal compounds. The results indicated that further research is necessary to develop with more structural modification novel obovatol-based botanical antifungal agents.


Corresponding author: Chun Yang, College of Plant Protection, Shanxi Agricultural University, Taigu, 030801, Shanxi Province, P. R. China, E-mail:

Award Identifier / Grant number: 31700300

Award Identifier / Grant number: 21702129

Award Identifier / Grant number: 2016YJ09

Award Identifier / Grant number: 2016YJ10

Funding source: Scientific and Technologial Innovation Programs of Higher Education Institutions

Award Identifier / Grant number: 2019L0403

Award Identifier / Grant number: 2019L0397

Award Identifier / Grant number: 201803D221012-1

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: The research was financially supported by the National Natural Science Foundation of China (Nos. 31700300, 21702129), the Science and Technology Innovation Fund of Shanxi Agricultural University (Nos. 2016YJ09, 2016YJ10), the Scientific and Technologial Innovation Programs of Higher Education Institutions in Shanxi (“STIP”, Nos. 2019L0403, 2019L0397), and Key R&D Program of Shanxi Province (201803D221012-1).

  3. Conflicts of interest: There were no conflicts of interest from the authors.

  4. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Ito, K., Iida, T., Ichino, K., Tsunezuka, M., Hattori, M., Namba, T. Chem. Pharm. Bull. 1982, 30, 3347–3353; https://doi.org/10.1248/cpb.30.3347.Search in Google Scholar

2. Rao, K. V., Davis, T. L. Planta Med. 1982, 45, 57–59; https://doi.org/10.1055/s-2007-971246.Search in Google Scholar

3. Koetter, U., Barrett, M., Lacher, S., Abdelrahman, A., Dolnick, D. J. Ethnopharmacol. 2009, 124, 421–425; https://doi.org/10.1016/j.jep.2009.05.040.Search in Google Scholar

4. Seo, K. H., Lee, D. Y., Lee, D. S., Park, J. H., Jeong, R. H., Jung, Y. J., Shrestha, S., Chung, I. S., Kim, G. S., Kim, Y. C., Baek, N. I. Planta Med. 2013, 79, 1335–1340; https://doi.org/10.1055/s-0033-1350673.Search in Google Scholar

5. Matsuda, H., Kageura, T., Oda, M., Morikawa, T., Sakamoto, Y., Yoshikawa, M. Chem. Pharm. Bull. 2001, 49, 716–720; https://doi.org/10.1248/cpb.49.716.Search in Google Scholar

6. Min, B. S. Nat. Prod. Sci. 2008, 14, 196–201.Search in Google Scholar

7. Choi, N. H., Choi, G. J., Min, B. S., Jang, K. S., Choi, Y. H., Kang, M. S., Park, M. S., Choi, J. E., Bae, B. K., Kim, J. C. J. Appl. Microbiol. 2009, 106, 2057–2063; https://doi.org/10.1111/j.1365-2672.2009.04175.x.Search in Google Scholar

8. Lee, Y. J., Lee, Y. M., Lee, C. K., Jung, J. K., Han, S. B., Hong, J. T. Pharmacol. Ther. 2011, 130, 157–176; https://doi.org/10.1016/j.pharmthera.2011.01.010.Search in Google Scholar

9. Vu, V. T., Liu, X. Q., Nguyen, M. T., Lin, Y. L., Kong, L. Y., Luo, J. G. Bioorg. Chem. 2020, 96, 103586; https://doi.org/10.1016/j.bioorg.2020.103586.Search in Google Scholar

10. Yang, C., Li, T., Jiang, L. Y., Zhi, X. Y., Cao, H. Bioorg. Chem. 2020, 94, 103469; https://doi.org/10.1016/j.bioorg.2019.103469.Search in Google Scholar

11. Lee, S. K., Kim, H. N., Kang, Y. R., Lee, C. W., Kim, H. M., Han, D. C., Shin, J., Bae, K., Kwon, B. M. Bioorg. Med. Chem. 2008, 16, 8397–8402; https://doi.org/10.1016/j.bmc.2008.08.033.Search in Google Scholar

12. Choi, M. S., Lee, S. H., Cho, H. S., Kim, Y., Yun, Y. P., Jung, H. Y., Jung, J. K., Lee, B. C., Pyo, H. B., Hong, J. T. Eur. J. Pharamacol. 2007, 556, 181–189; https://doi.org/10.1016/j.ejphar.2006.10.054.Search in Google Scholar

13. Ma, H., Jo, Y. J., Ma, Y., Hong, J. T., Kwon, B. M., Oh, K. W. Phytomedicine 2009, 16, 308–313; https://doi.org/10.1016/j.phymed.2008.12.007.Search in Google Scholar

14. Lee, Y. K., Song, J. K., Choi, I. S., Jeong, J. H., Moon, D. C., Yun, Y. P., Han, S. B., Oh, K. W., Hong, J. T. Eur. J. Pharamacol. 2010, 649, 168–176; https://doi.org/10.1016/j.ejphar.2010.09.029.Search in Google Scholar

15. Yang, E. J., Lee, J. Y., Park, S. H., Lee, T., Song, K. S. Food Chem. Toxicol. 2013, 56, 304–312; https://doi.org/10.1016/j.fct.2013.02.035.Search in Google Scholar

16. Kwak, J. H., Lee, S., Park, E. S., Song, J., Kim, Y. J., Choi, N. S., Lee, H., Yun, Y. P., Hong, J. T., Kwak, Y. S., Min, K. H., Jung, J. K. Arch Pharm. Res. (Seoul) 2011, 34, 1107–1112; https://doi.org/10.1007/s12272-011-0708-9.Search in Google Scholar

17. Choi, D. Y., Lee, J. W., Peng, J., Lee, Y. J., Han, J. Y., Lee, Y. H., Choi, I. S., Han, S. B., Jung, J. K., Lee, W. S., Lee, S. H., Kwon, B. M., Oh, K. W., Hong, J. T. J. Neurochem. 2012, 120, 1048–1059.10.1111/j.1471-4159.2011.07642.xSearch in Google Scholar

18. Laursen, J. B., Nielsen, J. Chem. Rev. 2004, 104, 1663–1686; https://doi.org/10.1021/cr020473j.Search in Google Scholar

19. Puopolo, G., Masi, M., Raio, A., Andolfi, A., Zoina, A., Cimmino, A., Evidente, A. Nat. Prod. Res. 2013, 27, 956–966; https://doi.org/10.1080/14786419.2012.696257.Search in Google Scholar

20. Chen, X., Hu, L. F., Huang, X. S., Zhao, L. X., Miao, C. P., Chen, Y. W., Xu, L. H., Han, L., Li, Y. Q. J. Agric. Food Chem. 2019, 67, 11403–11407; https://doi.org/10.1021/acs.jafc.9b04191.Search in Google Scholar

21. Lu, X. L., Zhu, X., Zhang, M., Wu, Q. L., Zhou, X. D., Li, J. K. Nat. Prod. Res. 2019, 33, 2145–2150.10.1080/14786419.2018.1489389Search in Google Scholar PubMed

22. Zhi, X. Y., Yang, C., Yu, X., Xu, H. Bioorg. Med. Chem. Lett. 2014, 24, 5679–5682; https://doi.org/10.1016/j.bmcl.2014.10.081.Search in Google Scholar

23. Prabhakar, C., Madhusudhan, G., Sahadev, K., Reddy, C. M., Sarma, M. R., Reddy, G. O., Chakrabarti, R., Rao, C. S., Kumar, T. D., Rajagopalan, R. Bioorg. Med. Chem. Lett. 1998, 8, 2725–2730; https://doi.org/10.1016/s0960-894x(98)00485-5.Search in Google Scholar

24. Zhi, X. Y., Jiang, L. Y., Li, T., Song, L. L., Wu, L. J., Cao, H., Yang, C. Bioorg. Chem. 2020, 97, 103696; https://doi.org/10.1016/j.bioorg.2020.103696.Search in Google Scholar

25. Zhi, X. Y., Jiang, L. Y., Li, T., Song, L. L., Wang, Y., Cao, H., Yang, C. Bioorg. Med. Chem. Lett. 2020, 30, 127086; https://doi.org/10.1016/j.bmcl.2020.127086.Search in Google Scholar

26. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

27. Sheldrick, G. M. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Search in Google Scholar

28. Sheldrick, G. M. Acta Crystallogr. 2015, C71, 3–8.Search in Google Scholar

Received: 2020-09-04
Accepted: 2021-01-04
Published Online: 2021-03-01
Published in Print: 2021-04-27

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 22.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/znb-2020-0158/html?lang=en
Scroll to top button